Amneal Pharmaceuticals Inc. (AMRX) Stock
Key stats
- Market cap
- $6.77B
- Price / Earnings ratio
- 40.5x
- EPS (TTM)
- $0.50
- Volume
- Loading
- 52-week high
- $21.68
- 52-week low
- $11.14
Source: third-party data provider, as of November 7, 2026
Compare with AMRX
Recent news
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
AMRX
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
AMRX
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
AMRX
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
AMRXNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 43.60
- MACD 12/26/9
- 0.25
- EMA 9 of MACD
- 0.41
- MACD histogram
- -0.15
- SMA 50
- $19.29
- Price above SMA 50
- EMA 50
- $19.47
- Price below EMA 50
- SMA 200
- $15.87
- Price above SMA 200
- EMA 200
- $16.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.22 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
What Amneal Pharmaceuticals (AMRX) Said on Its Q3 Earnings Call
AMRXAmneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say
AMRXAmneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top Estimates
AMRXAmneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
AMRX
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
AMRX
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
AMRX
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
AMRX
AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod
AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod
AMRX
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
AMRX
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
AMRXNews tone: automated (AI) classification of the article's content, not a price prediction.
About Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Chirag K. Patel | Co-Founder, Co-CEO, President & Director | 1967 |
| Mr. Chintu Patel R.Ph. | Co-Founder, Co-CEO & Director | 1972 |
| Mr. Anastasios G. Konidaris | Executive VP & CFO | 1967 |
| Mr. Jason B. Daly Esq. | Executive VP, Chief Legal Officer & Corporate Secretary | 1974 |
| Ms. Nikita Shah | Executive VP & Chief Human Resources Officer | 1978 |
| Mr. Andrew S. Boyer | Executive VP and Chief Commercial Officer of Generics & Biosciences | 1966 |
| Mr. Anthony DiMeo | Head/VP of Investor Relations | — |
| Brandon Skop | Senior Director of Corporate Communications | — |
| Mr. Gregory Sgammato | Senior Vice President of Corporate Development | — |
| Mr. Pranav Mehta | Senior VP of Strategic Sourcing & Supply Management | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 43.60
- MACD 12/26/9
- 0.25
- EMA 9 of MACD
- 0.41
- MACD histogram
- -0.15
- SMA 50
- $19.29
- Price above SMA 50
- EMA 50
- $19.47
- Price below EMA 50
- SMA 200
- $15.87
- Price above SMA 200
- EMA 200
- $16.24
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $24.25
- High
- $27.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -20.4 | +16.8 | ||||||||||
| 2022 | -8.7 | -1.9 | -6.3 | -10.2 | -9.9 | -14.1 | +5.4 | -38.7 | -13.7 | +5.8 | +9.9 | -22.6 |
| 2023 | +4.3 | -12.0 | -33.5 | +33.1 | +25.8 | +23.5 | +4.9 | +29.0 | +0.0 | -9.6 | +10.8 | +30.3 |
| 2024 | -10.5 | +0.2 | +10.8 | +0.0 | +9.2 | -3.9 | +14.2 | +20.6 | -2.0 | -2.6 | -2.6 | -7.6 |
| 2025 | +6.4 | +6.0 | -4.3 | -6.9 | -5.4 | +9.0 | -4.8 | +22.1 | +4.5 | +4.2 | +11.8 | +2.4 |
| 2026 | +8.1 | -2.7 | -9.7 | +1.3 | +2.7 | +34.2 | +8.0 | -7.3 | +13.9 | +7.2 | -4.8 |
